International Psoriasis Council

Room F1 + F2

Date: Wednesday 18 September 2019, 14.00-18.00
Room: F1 + F2

Program Title: The mechanistic model(s) of psoriasis: Autoimmune and/or autoinflammatory?

Program Summary

This symposium will explore recent advances in the understanding of both the adaptive and innate immune pathways that lead to clinical phenotypes of psoriasis. Part 1 of this event will feature five faculty presentations with expert panel discussion on the immunological spectrum of psoriasis whereby the adaptive immune response drives chronic plaque psoriasis and innate and autoinflammatory responses contribute to rare subtypes of psoriasis. The complex interplay among autoreactive T-cells, lipid driven T cell response, cytokines, and genetic mutations will be highlighted.

Michel Gilliet Lausanne, Switzerland) Johann Gudjonsson (Michigan, United States),  Jörg Prinz (Munich, Germany)



Welcome and Overview
Michel Gilliet (Lausanne)

14.05-14.30 Autoreactive T cells in psoriasis
Jörg Prinz (Munich)
14.30-14.55 Lipid driven T cell responses in psoriasis
Chyung-Ru Wang (Chicago, USA)
14.55-15.20 The role of self in the innate immune system
Michel Gilliet (Lausanne)
15.20-15.35 Break


15.35-16.00 The role of interleukin-36 pathway deregulation in pustular psoriasis and psoriasis vulgaris: the autoinflammatory side of psoriasis
Hervé Bachelez (Paris)
16.00-16.25 The impact of AP1S3 and CARD14 deregulation in psoriasis and psoriasis-like disorders
Francesca Capon (London)
16.25-16.55 Panel Discussion
Moderator: Johann Gudjonsson (Michigan, United States)


16.55-17.05 Poster 388
Treatment with spesolimab, an anti-interleukin-36 receptor antibody, in patients with generalized pustular psoriasis, is associated with the downregulation of biomarkers linked to innate, Th1/17 and neutrophilic pathways
Christian Thoma (Biberach)
17.05-17.15 Poster 281
CARD14 variants are associated with palmar plantar pustulosis
Athanasios Niaouris (London)
17.15-17.25 Poster 340
Circulating microRNAs in extracellular vesicles from plasma as potential biomarkers for psoriatic arthritis in patients with psoriasis
Lorenzo Pasquali (Stockholm)
17.25-17.35 Poster 054
A Selective Tyrosine Kinase 2 Inhibitor, BMS-986165, Decreases the Transcriptional Signature of Th17 , Interleukin-12, and Interferon Pathways in Skin of Psoriasis: Results From a Phase 2 Trial
Ian Catlett (Princeton, USA)

17.35-17.45 Poster 399
Distinct gene expression signatures differentiate clinical response to ustekinumab compared to adalimumab in psoriasis
Ashley Rider (Newcastle Upon Tyne)

17.45-17.55 Poster 360
miR-378a is overexpressed in psoriasis keratinocytes and potentiates IL-17A-mediated inflammatory responses
Enikö Pivarcsi Sonkoly (Stockholm)

17.55-18.00 Closing Comments
Jörg Prinz (Munich)